The US specialty generics business of German pharmaceutical firm Boehringer Ingelheim is to be bought by Jordanian firm Hikma for $2.65 billion in cash and stock.
The US specialty generics business of German pharmaceutical firm Boehringer Ingelheim is to be bought by Jordanian firm Hikma for $2.65 billion in cash and stock. The deal will increase the firm’s US presence and follows Monday’s announcement that Teva is buying the generics business of Allergan. Hikma already owns Boehringer’s former injectable generics business based in Ohio.
